IDXG - Interpace Diagnostics Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.53
-0.12 (-7.27%)
At close: 4:00PM EDT

1.55 +0.02 (1.31%)
After hours: 7:42PM EDT

Stock chart is not supported by your current browser
Previous Close1.65
Open1.63
Bid1.54 x 1100
Ask1.55 x 1000
Day's Range1.53 - 1.63
52 Week Range0.77 - 1.80
Volume574,696
Avg. Volume631,723
Market Cap43.137M
Beta3.82
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateAug 14, 2017 - Aug 18, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.19
Trade prices are not sourced from all markets
  • What Kind Of Shareholders Own Interpace Diagnostics Group Inc (NASDAQ:IDXG)?
    Simply Wall St.3 days ago

    What Kind Of Shareholders Own Interpace Diagnostics Group Inc (NASDAQ:IDXG)?

    The big shareholder groups in Interpace Diagnostics Group Inc (NASDAQ:IDXG) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insidersRead More...

  • GlobeNewswire5 days ago

    Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides beneficial molecular diagnostic tests and pathology services that improve patient diagnosis and management, announced today that the Company will participate in several local events in support of the following patient advocacy groups: Lustgarten Foundation Pancreatic Cancer Research (The Lustgarten Foundation), Thyroid, Head and Neck Cancer (THANC) Foundation, and Pancreatic Cancer Action Network (PanCAN). The Lustgarten Foundation and PanCAN are global organizations striving to advance scientific and medical research for pancreatic cancer in order to improve the lives of patients and their families.

  • Investopedia21 days ago

    Penny Stocks to Watch for September 2018

    Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.

  • Thomson Reuters StreetEvents28 days ago

    Edited Transcript of IDXG earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Interpace Diagnostics Group Inc Earnings Call

  • GlobeNewswirelast month

    Interpace Diagnostics to Present at the 10th Annual Next Generation Dx Summit 2018

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that the Company will present at the 10th Annual Next Generation Dx Summit, being held in Washington, DC from August 22-24, 2018. As part of the “Commercializing Molecular Diagnostics in Pharma, Healthcare and the Clinic” track, Interpace’s Chief Commercial Officer, Greg Richard, will host a presentation on how to navigate the disparate technology assessment processes employed by private and public payers and the specific methods Interpace has used to successfully secure coverage for its products, ThyGeNEXT™, ThyraMIR®, PancraGEN®, and RespriDx™.

  • GlobeNewswirelast month

    Interpace Diagnostics Acquires Select Assets of Rosetta Genomics Out of Bankruptcy

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated bioinformatics and commercial company that provides clinically useful molecular diagnostic tests, related first line assessments and pathology services for improved patient diagnosis and management, today announced that it has successfully acquired a majority of the equipment of Rosetta Genomics’ Philadelphia laboratory through a bankruptcy auction.  Interpace acquired, for an undisclosed amount of cash, 64 select lots of laboratory assets, including freezers, refrigerators, PCR machines, advanced slide scanning equipment as well as laboratory supplies and specialty furniture. The laboratory assets will further support the Company’s CLIA and CAP certified lab expansion in its Pittsburgh, PA and New Haven, CT laboratories.

  • GlobeNewswirelast month

    Interpace Diagnostics Group Reports Second Quarter 2018 Financial Results, Business Progress and Recent Accomplishments

    Revenue Grew 43% Over the Prior Year’ s Quarter and 14% Over the Prior Period. Record Quarterly Revenue of $5.5 Million. Cash & Cash Equivalents of $10.1 Million with No Long-Term Debt.

  • ACCESSWIRElast month

    Interpace Diagnostics Group, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM ...

  • ACCESSWIRElast month

    Interpace Diagnostics Group, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM ...

  • GlobeNewswire2 months ago

    Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Thursday, August 9, 2018

    Interpace Diagnostics Group, Inc., (“Interpace” or “the Company”) announced today that it will report its second quarter 2018 financial results after the close of market on Thursday, August 9, 2018 at 4:30 p.m. ET.

  • GlobeNewswire2 months ago

    Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, reported today that the Company has received a letter dated July 30, 2018 from the NASDAQ Listing Qualifications notifying the Company that it has regained compliance with the requirement of The NASDAQ Stock Market to maintain a minimum closing bid price of $1.00 per share. The letter noted that for the last 10 days from July 16, 2018 to July 27, 2018 the closing bid price of the Company’s common stock has been at $1.00 per share or greater.   Accordingly, NASDAQ informed the Company that it has regained compliance with Listing Rule 5550(a)(2) and that the matter was now closed.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus ...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Chemed, Sysco, Interpace Diagnostics Group, Navient, CenturyLink, and DENTSPLY SIRONA — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chemed ...

  • GlobeNewswire2 months ago

    Interpace Diagnostics Announces CIGNA’s Expansion of Coverage to Now Include ThyraMIR®

    Interpace previously announced, in 2017, CIGNA’s agreement to cover ThyGenX®, the Company’s next generation sequencing test for thyroid cancer risk assessment. ThyGenX® (now ThyGeNEXT™) and ThyraMIR®, utilized in combination, have both high sensitivity and specificity that corresponds to clinically actionable outcomes in a single testing service.

  • GlobeNewswire2 months ago

    Interpace Diagnostics Expands Application of Pancreatic Cancer Test

    Interpace Diagnostics Group, Inc. (IDXG) (the “Company” or “Interpace Diagnostics”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that the Company has expanded the application of PancraGEN® beyond pancreatic cysts to include both biliary strictures and solid pancreatic lesions while gaining further Guideline support in the marketplace. PancraGEN® is the first and only commercially available integrated molecular pathology test for pancreaticobiliary cancers.

  • Should You Buy Interpace Diagnostics Group Inc (NASDAQ:IDXG) At US$00.8855?
    Simply Wall St.3 months ago

    Should You Buy Interpace Diagnostics Group Inc (NASDAQ:IDXG) At US$00.8855?

    Interpace Diagnostics Group Inc (NASDAQ:IDXG), a healthcare company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highsRead More...

  • ACCESSWIRE3 months ago

    Stock Performance Review on IHS Markit and Three Other Business Services Stocks

    WallStEquities.com has initiated research reports on the following Business Services stocks: Global Payments Inc. (NYSE: GPN), HMS Holdings Corp. (NASDAQ: HMSY), IHS Markit Ltd (NASDAQ: INFO), and Interpace Diagnostics Group Inc. (NASDAQ: IDXG). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of IDXG earnings conference call or presentation 15-May-18 12:30pm GMT

    Q1 2018 Interpace Diagnostics Group Inc Earnings Call